Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia
Auto-generated profile, based on publicly available information
Tjokorda Gde Dalem Pemayun
Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia
BACKGROUND: Metabolic syndrome (MetS), which is characterized by insulin resistance, adipocyte accumulation, and obesity, has been linked to malignancy development. Both leptin, an adipose tissue-produced cytokine-like hormone, and adiponectin, a hormone secreted by adipose tissue, play roles in the progression of MetS. However, the presence of leptin and adiponectin is also assumed to be associated with cancer proliferation. Therefore, it is necessary to investigate the profile of leptin and adiponectin levels in MetS patients with malignancy and non-malignancy.METHODS: This was a cross-sectional study involving 80 MetS subjects with and without malignancy. Leptin and adiponectin levels of subjects were analyzed by using the enzyme-linked immunosorbent assay (ELISA) method. Mann-Whitney tests were used to compare leptin and adiponectin levels between groups.RESULTS: Leptin levels were significantly higher in MetS patients with malignancy (32.99±22.47 ng/mL) than those without malignancy (6.17±7.46 ng/mL). Conversely, adiponectin levels were lower in the malignancy group (10.11±7.66 µg/mL) compared to the non-malignancy group (13.44±8.29 µg/mL), with both differences being statistically significant (p<0.001 for leptin, p=0.023 for adiponectin).CONCLUSION: Leptin levels were found to be higher while adiponectin levels were found to be lower in MetS patients with malignancy compared to those without malignancy. Therefore, it is suggested that leptin and adiponectin levels might be used as malignancy markers in MetS patients.KEYWORDS: adiponectin, leptin, metabolic syndrome, malignancy
1 January 2024 in Journal of Lipid and Atherosclerosis
Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is common liver disease often found and occurs in community. Prevalence of liver disease (NAFLD) has risen rapidly along with an increase obesity incidence in women. Inflammation condition in obese condition causing an increase in IL-6, Platelets Count (PLTC), and Aldosterone level increased risk of developing NAFLD. Aim: To analyze differences IL-6, PLTC, and Aldosterone level between Obese and Non-Obese Women. Methods: This study was an observational cross-sectional analytical study that conduct in NovemberJanuari 2021 at Diponegoro National Hospital (RSND) Semarang. Inclusion criteria for respondent in this study were being middle-aged women (30-49 years), healthy, and willing to take part in this study. Total respondent in this study was 60 people then divided into two groups that is Obese and Non-Obese Group. The degree of fatty liver was examined using the ultrasound method. Platelete count (PLTC) were measured by Indico Blood Analyzer. Meanwhile IL-6 and Aldosterone level analyzed by the enzyme-linked immunosorbent assay (ELISA) method. Fatty liver was diagnosed by abdominal ultrasound. Data were analyze using SPSS 18.0 that including normality, different test, and regression test. Result: Incidence of fatty liver in the obese group was significantly different from the non-obese group (p 0.005). No significant different average aldosterone serum, and AST between two group. Platelete Count (PLTC), IL-6 between two groups was showed significantly difference between two group. Conclusion: Obesity will trigger an increase in IL-6 and PLT which can increase the risk of fatty liver.